Soligenix Inc. Reports Q2 2025 Results with Progress in Rare Disease Treatments
TL;DR
Soligenix's advancements in rare disease treatments, including Phase 2a results for SGX302 in psoriasis and Phase 3 trial of HyBryte(TM) for CTCL, offer investors potential growth opportunities.
Soligenix reported a Q2 2025 net loss of $2.7 million, with R&D expenses rising to $1.7 million due to increased trial and manufacturing costs, while maintaining $5.1 million in cash.
Soligenix's development of treatments for rare diseases like CTCL and Behçet’s Disease represents a significant step forward in improving patient care and quality of life.
Soligenix transfers synthetic hypericin manufacturing to the U.S., marking a strategic move in its partnership with Sterling Pharma Solutions for rare disease treatments.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases, has shared its Q2 2025 financial results and recent milestones, underscoring significant progress in its late-stage pipeline. The company anticipates top-line Phase 2a results for SGX302, a treatment for mild-to-moderate psoriasis, by the end of the year. Additionally, updates from an investigator-initiated study of HyBryte(TM) for early-stage cutaneous T-cell lymphoma (CTCL) are expected, alongside active enrollment in a confirmatory Phase 3 trial for the same condition, with results projected for 2026.
Furthering its commitment to addressing rare diseases, Soligenix completed a Phase 2a proof-of-concept study for SGX945 in Behçet’s Disease, meeting its primary objective of demonstrating biological efficacy. The company also successfully transferred the manufacturing of synthetic hypericin to the U.S. under its partnership with Sterling Pharma Solutions, marking a strategic step towards scaling production capabilities.
Financially, Soligenix reported a Q2 net loss of $2.7 million, or ($0.82) per share, an increase from $1.6 million in the previous period. This was attributed to rising research and development expenses, which climbed to $1.7 million due to higher trial and manufacturing costs. Despite these challenges, the company maintains a cash position of $5.1 million as of June 30, 2025, supplemented by an additional $1.4 million raised on July 1, ensuring funding for operations into Q1 2026.
The advancements in Soligenix's pipeline, particularly in treatments for psoriasis and CTCL, represent potential breakthroughs in areas with significant unmet medical needs. For more information on Soligenix's developments, visit https://www.Soligenix.com.
Curated from InvestorBrandNetwork (IBN)
